SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer

In conclusion, SNHG14 silencing suppressed NSCLC progression at least partly by miR-34a/HMGB1 axis in vitroand promoted NSCLC cell sensitivity to CDDP, highlighting that SNHG14 might be a potential target for NSCLC therapy.Graphical abstractThe mechanism schematic model by SNHG14/miR-34a/HMGB1 axis. SNHG14 expression was decreased in NSCLC cells by transfection of si-SNHG14. Then, miR-34a expression was upregulated. Next, upregulated miR-34a inhibited HMGB1 expression. Finally, low HMGB1 level repressed NSCLC cell migration and invasion, and enhanced cell apoptosis and cell sensitivity to CDDP, thereby suppressing NSCLC progression in vitro.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research